Evaluate Group’s EP Vantage pharma and biotech preview of 2018 predicts that the uptick in the pharmaceutical and biotech sectors that occurred in 2017 is likely to continue into 2018.
Evaluate's EP Vantage pharma and biotech preview of what’s in store for the industry in 2018 predicts that the uptick in the pharmaceutical and biotech sectors that occurred in 2017 is likely to continue into 2018, with more new medications expected to hit the market and with investors’ support for biopharma remaining strong. In addition, global demographic trends signal a rising demand for healthcare and medications. EP Vantage is the editorial arm of Evaluate Ltd, which provides commercial intelligence forecasts within the global life science industry.
New medicines are reaching the market more quickly than ever before, the report notes, with large and small drug developers successfully launching “transformative” products in a number of therapy areas over the last few years. The report cites the current business-friendly environment at the FDA as supporting the industry and being unlikely to change in the next year. FDA Commissioner Scott Gottlieb, MD, has been widely embraced by industry and investors. The FDA is on track to approve 43 novel drugs before the close of 2017, those drugs are forecast to generate a combined $32 billion in US sales in 5 years, and the FDA is now perceived as allowing greater leniency in its approval process (though the FDA strenuously denies that it has lowered hurdles for approval). The report cites Amicus’s Fabry disease treatment migalastat (Galafold) as an example of a “friendlier” FDA.
The report highlights the following key points:
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Trastuzumab-dkst Shows Promising Results in Real-World Setting for HER2+ Breast Cancer
July 9th 2024A Brazilian real-world study found trastuzumab-dkst to be an effective and safe adjuvant therapy for HER2-positive (HER2+) breast cancer, with clinical outcomes comparable to reference trastuzumab.